

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s inosine/cn

L1 1 INOSINE/CN

=> d L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 58-63-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN Inosine (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1,9-Dihydro-9- β -D-ribofuranosyl-6H-purin-6-one

CN 6H-Purin-6-one, 1,9-dihydro-9- β -D-ribofuranosyl-

CN 9- β -D-Ribofuranosylhypoxanthine

CN Atorel

CN HXR

CN Hypoxanthine 9- β -D-ribofuranoside

CN Hypoxanthine ribonucleoside

CN Hypoxanthine riboside

CN Hypoxanthine, 9- β -D-ribofuranosyl-

CN Hypoxanthosine

CN Ino

CN Inosie

CN NSC 20262

CN Oxiamin

CN Panholic-L

CN Ribonosine

CN Selfer

CN Trophicardyl

FS STEREOSEARCH

DR 691344-25-9, 740029-83-8, 12712-98-0, 132953-54-9, 4181-51-5, 28861-88-3, 292853-81-7

MF C10 H12 N4 O5

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSChem, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6030 REFERENCES IN FILE CA (1907 TO DATE)
191 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6040 REFERENCES IN FILE CAPLUS (1907 TO DATE)
86 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s arginine/cn

L2 2 ARGININE/CN

=> d L2 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 7200-25-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN Arginine (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Arginine, DL- (8CI)

CN DL-Arginine

OTHER NAMES:

CN (±)-Arginine

FS 3D CONCORD

MF C6 H14 N4 O2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DETHERM*, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, NAPRALERT, PIRA, PROMT, TOXCENTER, TULSA, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

360 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
360 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 74-79-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Arginine (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Arginine, L- (8CI)
 OTHER NAMES:
 CN (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
 CN Arginine
 CN L-(+)-Arginine
 CN L- α -Amino- δ -guanidinovaleric acid
 CN L-Arg
 CN L-Norvaline, 5-[(aminoiminomethyl)amino]-
 CN L-Ornithine, N5-(aminoiminomethyl)-
 CN NSC 206269
 CN Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-
 FS STEREOSEARCH
 DR 667422-95-9, 7004-12-8, 142-49-4
 MF C6 H14 N4 O2
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU,
 EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
 MSDS-OHS, NAPRALERT, PATDPASPC, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO,
 SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

44093 REFERENCES IN FILE CA (1907 TO DATE)
 1275 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 44173 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> exp inosine

E1	269	INOSINATE/BI
E2	344	INOSINATO/BI
E3	5157 -->	INOSINE/BI
E4	1	INOSINEDI/BI
E5	1	INOSINEDICARBOX/BI
E6	1	INOSINEDICARBOXALDEHYDE/BI
E7	3	INOSINEMONO/BI
E8	3	INOSINEMONOPHOSPH/BI
E9	3	INOSINEMONOPHOSPHATE/BI
E10	1	INOSINEN/BI
E11	2	INOSINESIDE/BI
E12	999	INOSINIC/BI

=> exp inosine/cn

E1	1	INOSINATE NUCLEOSIDASE/CN
E2	1	INOSINATE PYROPHOSPHORYLASE/CN
E3	1 -->	INOSINE/CN
E4	1	INOSINE (5'-), 5'-(PENTAHYDROGEN TETRAPHOSPHATE)/CN

```

E5          1      INOSINE 2',3',5'-TRINITRATE/CN
E6          1      INOSINE 2',5'-DIPHOSPHATE/CN
E7          1      INOSINE 2'-MONOPHOSPHATE/CN
E8          1      INOSINE 3',5'-CYCLIC MONOPHOSPHATE/CN
E9          1      INOSINE 3',5'-DIPHOSPHATE/CN
E10         1      INOSINE 3',5'-DIPHOSPHATE, 5'-ANHYDRIDE WITH H2SO4/CN
E11         1      INOSINE 3',5'-MONOPHOSPHATE/CN
E12         1      INOSINE 3'-(HEXAHYDROGEN PENTAPHOSPHATE), 3'.FWDARW.5'-ESTER
                   WITH 2',3'-O-(1-ETHOXY-2-(((PHENYLMETHOXY) CARBONYL) AMINO) PR
                   OPYLIDENE) INOSINE/CN

```

```

=> sel L1
E1 THROUGH E27 ASSIGNED

```

```

=> sel L2
E28 THROUGH E44 ASSIGNED

```

```

=> index bioscience patents

```

```

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

```

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	17.09	17.30

```

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:23:09 ON 12 JUL 2006

```

```

92 FILES IN THE FILE LIST IN STNINDEX

```

```

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

```

```

=> s (E1-E27) and (E28-E44)
      2  FILE ADISCTI
      5  FILE AGRICOLA
      5  FILE ANABSTR
    5 FILES SEARCHED...
      29 FILE AQUASCI
      3  FILE BIOENG
      88 FILE BIOSIS
   10 FILES SEARCHED...
      17 FILE BIOTECHABS
      17 FILE BIOTECHDS
      24 FILE BIOTECHNO
   13 FILES SEARCHED...
      20 FILE CABA
     396 FILE CAPLUS
      2  FILE CEABA-VTB
      2  FILE CROPU
      2  FILE DDFB
   21 FILES SEARCHED...
      9  FILE DDFU
     39 FILE DGENE
   23 FILES SEARCHED...
      8  FILE DISSABS
      2  FILE DRUGB
      5  FILE DRUGMONOG2
     10 FILE DRUGU
     84 FILE EMBASE
     34 FILE ESBIODASE
   30 FILES SEARCHED...
      1  FILE FROSTI
     30 FILE FSTA

```

308 FILE GENBANK
 35 FILES SEARCHED...
 63 FILE IFIPAT
 11 FILE JICST-EPLUS
 26 FILE LIFESCI
 82 FILE MEDLINE
 45 FILES SEARCHED...
 11 FILE OCEAN
 23 FILE PASCAL
 48 FILES SEARCHED...
 1 FILE PHIN
 4 FILE PROMT
 1 FILE RDISCLOSURE
 57 FILES SEARCHED...
 71 FILE SCISEARCH
 81 FILE TOXCENTER
 7417 FILE USPATFULL
 659 FILE USPAT2
 62 FILES SEARCHED...
 54 FILE WPIDS
 66 FILES SEARCHED...
 54 FILE WPINDEX
 68 FILES SEARCHED...
 2 FILE DPCI
 527 FILE EPFULL
 73 FILES SEARCHED...
 93 FILE FRFULL
 75 FILES SEARCHED...
 53 FILE GBFULL
 7 FILE INPADOC
 2 FILE JAPIO
 79 FILES SEARCHED...
 84 FILES SEARCHED...
 3 FILE PATDPAFULL
 85 FILES SEARCHED...
 6553 FILE PCTFULL
 87 FILES SEARCHED...
 1 FILE PIRA

49 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L3 QUE ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI OR "HYPOXANTHINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-D-RIBOFURANOSIDE"/BI OR "HYPOXANTHINE, 9-B-D-RIBOFURANOSYL-"/BI OR HYPOXANTHOSINE/BI OR INO/BI OR INOSIE/BI OR INOSINE/BI OR "NSC 20262"/BI OR OXIAMIN/BI OR PANHOLIC-L/BI OR RIBONOSINE/BI OR SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 132953-54-9/BI OR 28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58-63-9/BI OR "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR 691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOXANTHINE/BI)) AND ((ARGININE/BI OR "(±)-ARGININE"/BI OR "(S)-2-AMINO-5-((AMINOIMINOMETHYL)AMINO)PENTANOIC ACID"/BI OR DL-ARGININE/BI OR "L-A-AMINO-Δ-GUANIDINOVALERIC ACID"/BI OR "L-(+)-ARGININE"/BI OR L-ARG/BI OR L-ARGININE/BI OR "L-NORVALINE, 5-((AMINOIMINOMETHYL)AMINO)-"/BI OR "L-ORNITHINE, N5-(AMINOIMINOMETHYL)-"/BI OR "NSC 206269"/BI OR "PENTANOIC ACID, 2-AMINO-5-((AMINOIMINOMETHYL)AMINO)-, (S)-"/BI OR 142-49-4/BI OR 667422-95-9/BI OR 7004-12-8/BI OR 7200-25-1/BI OR 74-79-3/BI))

=> file file bioses embase medline uspatfull pecfull epfull caplus
 'FILE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

'BIOSSES' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):biosis

'PECFULL' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.03

31.33

FILE 'BIOSIS' ENTERED AT 13:36:40 ON 12 JUL 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:36:40 ON 12 JUL 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:36:40 ON 12 JUL 2006

FILE 'USPATFULL' ENTERED AT 13:36:40 ON 12 JUL 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:36:40 ON 12 JUL 2006

COPYRIGHT (C) 2006 Univentio

FILE 'EPFULL' ENTERED AT 13:36:40 ON 12 JUL 2006

COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'CAPLUS' ENTERED AT 13:36:40 ON 12 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (E1-E27) and (E28-E44)

2 FILES SEARCHED...

4 FILES SEARCHED...

5 FILES SEARCHED...

6 FILES SEARCHED...

L4 15147 ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI OR "HYPOXANTHINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-D-RIBOFURAN OSIDE"/BI OR "HYPOXANTHINE, 9-B-D-RIBOFURANOSYL-"/BI OR HYPOXANTHOSINE/BI OR INO/BI OR INOSIE/BI OR INOSINE/BI OR "NSC 20262"/BI OR OXIAMIN/BI OR PANHOLIC-L/BI OR RIBONOSINE/BI OR SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIHYDRO-9-B-D-RIBOFURAN OSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 132953-54-9/BI OR 28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58-63-9/BI OR "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR 691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOX ANTHINE/BI)) AND ((ARGININE/BI OR "(±)-ARGININE"/BI OR "(S)-2-AMINO-5-((AMINOIMINOMETHYL)AMINO)PENTANOIC ACID"/BI OR DL-ARGININ E/BI OR "L-A-AMINO-Δ-GUANIDINOVALERIC ACID"/BI OR "L-(+)-ARGININE"/BI OR L-ARG/BI OR L-ARGININE/BI OR "L-NORVALINE, 5-((AMINOIMINOMETHYL)AMINO)-"/BI OR "L-ORNITHINE, N5-(AMINOIMINO METHYL)-"/BI OR "NSC 206269"/BI OR "PE

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

222.45

253.78

FILE 'REGISTRY' ENTERED AT 13:38:34 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> exp arginine/cn

E1	1	ARGININANILIDE, NA,N Ω ,N Ω -TRIS(PHENYLCARBAM
		OYL)-, L-/CN
E2	1	ARGININANILIDE, N2-BENZOYL-/CN
E3	2 -->	ARGININE/CN
E4	1	ARGININE B-NAPHTHYLAMIDE/CN
E5	1	ARGININE 2,2,2-TRICHLOROETHYL ESTER/CN
E6	1	ARGININE 2,3-AMINOMUTASE/CN
E7	1	ARGININE 2,3-AMINOMUTASE (STREPTOMYCES GRISEOCHROMOGENES GEN
		E BLSG)/CN
E8	1	ARGININE 2-MONOOXYGENASE/CN
E9	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
		SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN
E10	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
		SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN
E11	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
		SCHERICHIA COLI STRAIN O157:H7 GENE ECS0943)/CN
E12	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E
		SCHERICHIA COLI STRAIN O157:H7 GENE ECS0946)/CN

=> exp arginine inosinate/cn

E1	1	ARGININE HYDROXAMATE/CN
E2	1	ARGININE HYDROXAMATE RESISTANCE PROTEIN (CORYNEBACTERIUM GLU
		TAMICUM STRAIN ATCC_13032 CLONE RXA02159)/CN
E3	0 -->	ARGININE INOSINATE/CN
E4	1	ARGININE KINASE/CN
E5	1	ARGININE KINASE (APIS MELLIFERA GENE ARGK ISOENZYME C REDUCE
		D)/CN
E6	1	ARGININE KINASE (BACILLUS CEREUS STRAIN ATCC 14579 GENE BC01
		01)/CN
E7	1	ARGININE KINASE (BATILLUS CORNUTUS)/CN
E8	1	ARGININE KINASE (CALLINECTES SAPIDUS GILL)/CN
E9	1	ARGININE KINASE (CARCINUS MAENAS GILL GENE AK)/CN
E10	1	ARGININE KINASE (CHLAMYDIA PNEUMONIAE GENE KARG)/CN
E11	1	ARGININE KINASE (CHLAMYDIA PNEUMONIAE STRAIN J138 GENE KARG)
		/CN
E12	1	ARGININE KINASE (CHLAMYDIA TRACHOMATIS STRAIN A/HAR-13 GENE
		KARG)/CN

```

=> file file bioses embase medline uspatfull pecfull epfull caplus
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'BIOSES' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):biosis
'PECFULL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):pctfull
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                               0.44      254.22

FILE 'BIOSIS' ENTERED AT 13:39:17 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:39:17 ON 12 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 13:39:17 ON 12 JUL 2006

FILE 'USPATFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
COPYRIGHT (C) 2006 Univentio

FILE 'EPFULL' ENTERED AT 13:39:17 ON 12 JUL 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

FILE 'CAPLUS' ENTERED AT 13:39:17 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 14 and solubility
L5          9456 L4 AND SOLUBILITY

=> s 15 and agrinine
L6          5 L5 AND AGRININE

=> s 15 and (arginine(w)inosinate)
L7          0 L5 AND (ARGININE(W) INOSINATE)

=> s 15 and (inosine(w)arginate)
L8          0 L5 AND (INOSINE(W) ARGINATE)

=> s 15 and salt
L9          8073 L5 AND SALT

=> s 1( not py>2000
MISSING OPERATOR 'L( NOT'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

```


=> s l5 not py>2000
L10 1830 L5 NOT PY>2000

=> d L10 1-10 ti

L10 ANSWER 1 OF 1830 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI CHANGES IN NITROGEN COMPOUNDS OF FERMENTED SAUSAGE DURING RIPENING WITH
LACTOBACILLUS-PLANTARUM.

L10 ANSWER 2 OF 1830 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY
NUCLEOTIDES AND THEIR COMPONENTS.

L10 ANSWER 3 OF 1830 USPATFULL on STN

TI Glutathione-S-conjugate transport in plants

L10 ANSWER 4 OF 1830 USPATFULL on STN

TI PGC-1, a novel brown fat PPAR γ coactivator

L10 ANSWER 5 OF 1830 USPATFULL on STN

TI Telomerase catalytic subunit

L10 ANSWER 6 OF 1830 USPATFULL on STN

TI Protein phosphatase-related molecules

L10 ANSWER 7 OF 1830 USPATFULL on STN

TI Tao protein kinases and methods of use therefor

L10 ANSWER 8 OF 1830 USPATFULL on STN

TI Vesicle transport protein

L10 ANSWER 9 OF 1830 USPATFULL on STN

TI Metal-regulated transporters and uses therefor

L10 ANSWER 10 OF 1830 USPATFULL on STN

TI Human pinin splice variant

=> s arginine/ti

L11 57015 ARGININE/TI

=> d L11 1-10 ti

L11 ANSWER 1 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI Cachectic tumor (MAC16) induces poor post-operative response with
arginine deficiency.

L11 ANSWER 2 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI The effects of L-arginine on the cardiac function of advanced
stage of myocardial reperfusion of rats in vivo.

L11 ANSWER 3 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI Increasing NO bioavailability though L-arginine supplementation
or arginase inhibition augments reflex cutaneous vasodilation in aged
skin.

L11 ANSWER 4 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI Chronic administration of NG-nitro-L-arginine methyl ester
(L-NAME) on endothelium-dependent relaxation of porcine brachial and

femoral arteries.

- L11 ANSWER 5 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Arginine therapy in transgenic-knockout sickle mice improves vascular reactivity by decreasing hemolysis and oxidative stress.
- L11 ANSWER 6 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Critical functional role of arginine 75 in connexin 26 gap-junction channels and hemichannels.
- L11 ANSWER 7 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Oral L-arginine supplementation increases VEGF in exhaled breath condensate (EBC) but not serum during acute ascent to 4383 m.
- L11 ANSWER 8 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Arginine 466 in human Organic Anion Transporter 1 confers chloride sensitivity.
- L11 ANSWER 9 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Fluoxetine inhibits arginine vasopressin (AVP)-stimulated water permeability in rat inner medullary collecting duct (IMCD) via alpha-2 mechanism.
- L11 ANSWER 10 OF 57015 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI The immuno-modulatory effects of ornithine alpha-ketoglutarate, arginine, and glutamine in postoperative rats with parenteral nutrition.

=> s arginine/ti and inosine/ti

L12 12 ARGININE/TI AND INOSINE/TI

=> d L12 1-12 ti

- L12 ANSWER 1 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and arginine 393.
- L12 ANSWER 2 OF 12 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.
- L12 ANSWER 3 OF 12 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani: The role of conserved residues, aspartate 389 and arginine 393.
- L12 ANSWER 4 OF 12 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Thermodynamic and kinetic parameters of oligonucleotide - oligopeptide interactions. Specificity of arginine inosine association.
- L12 ANSWER 5 OF 12 MEDLINE on STN
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and

arginine 393.

L12 ANSWER 6 OF 12 MEDLINE on STN
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.

L12 ANSWER 7 OF 12 USPATFULL on STN
TI Inosine L-Arginine salt and uses thereof

L12 ANSWER 8 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L12 ANSWER 9 OF 12 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN INOSINIE/L−ARGININE SALT AND USE THEREOF.
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION.

L12 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Functional Analysis of an Inosine-Guanosine Transporter from Leishmania donovani: The Role of Conserved Residues, Aspartate 389 and Arginine 393

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
TI Thermodynamic and kinetic parameters of oligonucleotide-oligopeptide interactions. Specificity of arginine.cntdot.inosine association

=> dup rem L12
PROCESSING COMPLETED FOR L12
L13 5 DUP REM L12 (7 DUPLICATES REMOVED)

=> d l13 1-7 ti

L13 ANSWER 1 OF 5 USPATFULL on STN
TI Inosine L-Arginine salt and uses thereof

L13 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN DUPLICATE
DUPLICATE 1
TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter

L13 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 2
TI Functional analysis of an inosine-guanosine transporter from Leishmania donovani. The role of conserved residues, aspartate 389 and arginine 393.

L13 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 3
TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.

=> d L13 1 2 3 5 ti abs bib

L13 ANSWER 1 OF 5 USPATFULL on STN

TI Inosine L-Arginine salt and uses thereof

AB The present invention discloses an inosine. L-arginine salt, compositions containing the salt, and methods of using the salt and said compositions for cell activation and/or plant growth promotion. The salt can be stored and transported as a solid and dissolves quickly and efficiently when needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:247954 USPATFULL

TI Inosine L-Arginine salt and uses thereof

IN Kurauchi, Masahiko, Kanagawa, JAPAN

Miyazawa, Yuki, Kanagawa, JAPAN

Sato, Hiroyuki, Kanagawa, JAPAN

PI US 2004192553 A1 20040930

AI US 2004-808536 A1 20040325 (10)

RLI Continuation of Ser. No. WO 2002-JP9184, filed on 10 Sep 2002, UNKNOWN

PRAI JP 2001-297011 20010927

DT Utility

FS APPLICATION

LREP AJINOMOTO CORPORATE SERVICES, LLC, INTELLECTUAL PROPERTY DEPARTMENT,
1120 CONNECTICUT AVE., N.W., WASHINGTON, DC, 20036

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 368

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN DUPLICATE
DUPLICATE 1

TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF

TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

ABEN A novel substance inosine/L-arginine salt and a cell activator or a plant growth promoter prepared by dissolving the salt in water. These agents are inosine preparations which can be distributed as a solid product and quickly dissolved before using.

ABFR La presente invention concerne une nouvelle substance, un sel d'inosine/de L-arginine et un activateur cellulaire ou promoteur de croissance vegetale prepare par dissolution du sel dans l'eau. Les agents sont des preparations d'inosine qui peuvent etre distribuees sous la forme d'un produit solide et dissoutes rapidement avant utilisation.

AN 2003029265 PCTFULL ED 20030416 EW 200315

TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF

TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

IN KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];

MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];

SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP]

PA AJINOMOTO CO., INC., 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JP [JP, JP], for all designates States except US;

KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;

MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;

SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only

AG SHIMOKOSHI, Masao, 9th Fl., Taka-ai Bldg., 15-2, Nihombashi 3-chome,

Chuo-ku, Tokyo 103-0027, JP

LAF Japanese
 LA Japanese
 DT Patent
 PI WO 2003029265 A1 20030410
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
 MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN
 TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL
 PT SE SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2002-JP9184 A 20020910
 PRAI JP 2001-2001-297011 20010927

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Inosine arginine salt for cell activity-stimulating
 agent and plant growth promoter
 AB The L-arginine salt of inosine (I) enhances the solubility of inosine and
 enables easy translocation of the inosine. The L-arginine and inosine
 form salt at 1:1 ratio. I is useful for stimulation of cell activity and
 promotion of plant growth such as rooting. Preparation of I and promotion of
 growth of bent grass with I were shown.

AN 2003:257896 CAPLUS
 DN 138:250168
 TI Inosine arginine salt for cell activity-stimulating
 agent and plant growth promoter
 IN Kurauchi, Masahiko; Miyazawa, Yoshinori; Sato, Hiroyuki
 PA Ajinomoto Co., Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003096090	A2	20030403	JP 2001-297011	20010927
	WO 2003029265	A1	20030410	WO 2002-JP9184	20020910
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	CN 1547585	A	20041117	CN 2002-816591	20020910
	US 2004192553	A1	20040930	US 2004-808536	20040325
PRAI	JP 2001-297011	A	20010927		
	WO 2002-JP9184	A1	20020910		

L13 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 DUPLICATE 3
 TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE
 INTERACTIONS SPECIFICITY OF ARGININE INOSINE
 ASSOCIATION.
 AB Field-jump techniques provide a very useful method for the investigation
 of protein-nucleic acid interactions. Electric field pulses induce the
 dissociation of nucleotide-peptide complexes by a dissociation field
 effect. Amplitudes and time constants of this effect can be used to

determine both thermodynamic and kinetic parameters. This method, as well as conventional UV absorbance and circular dichroism titrations, is applied to study the interaction of various combinations of the oligonucleotides (A)4, (A)5, (A)6, (dA)6, (I)6, (U)6 and (C)6 (all lacking terminal phosphates) with oligopeptides (Lys)2, (Lys)3, (Arg)2, (Arg)3, Lys-Gly-Lys, Lys-Phe-Lys, Lys-Tyr-Lys and Lys-Trp-Lys. As demonstrated by chain length dependences the affinity increases with an increasing number of negative charges on the oligonucleotide and of positive charges on the oligopeptide. In addition to these electrostatic effects there are some more specific interactions, demonstrated by the fact that the stability constant for the interaction of (I)6 with (Arg)3 is higher by a factor of 4 than the corresponding constant obtained with (Lys)3. This effect is attributed to H-bonding between the guanidino group of arginine and the hypoxanthine base. The data obtained with peptides containing aromatic residues reveal only relatively weak interactions of these residues with the bases of the oligonucleotides. The dynamics of the oligonucleotide-oligopeptide interactions are characterized by very high rates. The complex formation is a diffusion-controlled reaction with some acceleration due to electrostatic attraction effects. The lifetime of the complexes investigated is in the microsecond time range.

AN 1978:231393 BIOSIS
 DN PREV197866043890; BA66:43890
 TI THERMODYNAMIC AND KINETIC PARAMETERS OF OLIGO NUCLEOTIDE OLIGO PEPTIDE INTERACTIONS SPECIFICITY OF ARGININE INOSINE ASSOCIATION.
 AU PORSCHE D [Reprint author]
 CS MAX-PLACK-INST BIOPHYS CHEM, POSTFACH 968, D-3400 GOETTINGEN-NIKOLAUSBERG, W GER
 SO European Journal of Biochemistry, (1978) Vol. 86, No. 1, pp. 291-300. CODEN: EJBCAI. ISSN: 0014-2956.
 DT Article
 FS BA
 LA ENGLISH

=> s arginine/ab and inosine/ab
 L14 223 ARGININE/AB AND INOSINE/AB

=> s L14 and solubility/ab
 L15 2 L14 AND SOLUBILITY/AB

=> d L14 1-2 ti abs bib

L14 ANSWER 1 OF 223 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA.
 AB Bacterial tRNA adenosine deaminases (TadAs) catalyze the hydrolytic deamination of adenosine to inosine at the wobble position of tRNA(Arg2), a process that enables this single tRNA to recognize three different arginine codons in mRNA. In addition, inosine is also introduced at the wobble position of multiple eukaryotic tRNAs. The genes encoding these deaminases are essential in bacteria and yeast, demonstrating the importance of their biological activity. Here we report the crystallization and structure determination to 2.0 angstrom of Staphylococcus aureus TadA bound to the anticodon stem-loop of tRNAArg2 bearing nebularine, a non-hydrolyzable adenosine analog, at the wobble position. The cocrystal structure reveals the basis for both sequence and structure specificity in the interactions of TadA with RNA, and it additionally provides insight into the active site architecture that promotes efficient hydrolytic deamination.
 AN 2006:272371 BIOSIS
 DN PREV200600276598
 TI Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA.

AU Losey, Heather C.; Ruthenburg, Alexander J.; Verdine, Gregory L. [Reprint Author]
 CS Harvard Univ, Dept Chem and Biol Chem, Cambridge, MA 02138 USA
 gregory_verdine@harvard.edu
 SO Nature Structural & Molecular Biology, (FEB 2006) Vol. 13, No. 2, pp. 153-159.
 ISSN: 1545-9985.
 DT Article
 LA English
 ED Entered STN: 17 May 2006
 Last Updated on STN: 17 May 2006

L14 ANSWER 2 OF 223 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Nitrogen oxide blockade does not aggravate the endothelin-1-induced myocardial ischemia and release of purine metabolites from the dog heart.

AB Increased intrapericardial levels of endothelin-1 (ET-1) induce myocardial ischemia and concomitant release of the purine metabolites adenosine (ADO), inosine (INO) and hypoxanthine (HXA) into the pericardial fluid. However, the potential modulatory role of nitrogen monoxide in compensating the ET-1-induced ischemic stress is not fully elucidated. The pericardial elevations of purine metabolite concentrations in the pericardial fluid after ET-1 administration (150 pmol/kg intrapericardially) were measured in the in situ dog heart with (n = 6) or without (n = 5) systemic nitrogen monoxide synthase blockade (30 mg/kg (G)-nitro-L-arginine methyl ester, followed by 6 mg/min intravenously). After control sampling, three consecutive pericardial infusate samples (ET1, ET2, ET3) were obtained for purine metabolite determinations (high-performance liquid chromatography-ultraviolet). It was found that intrapericardial ET-1 elevated the pericardial purine metabolite concentrations significantly in both groups. No significant differences were detected between the control and (G)-nitro-L-arginine methyl ester-treated groups in ischemic changes of pericardial ADOmax (+3.27 +/- 1.13 muM versus +1.84 +/- 0.56 muM), INOmax (+15.21 +/- 2.3 muM versus +12.09 +/- 4.04 muM and HXAmx (+16.34 +/- 2.98 muM versus +17.09 +/- 5.22muM levels and in the maximal ST elevations (0.43 +/- 0.05 mV versus 0.61 +/- 0.08 mV). The hemodynamic variables did not change with ET-1 administration. In conclusion, systemic nitrogen monoxide synthase blockade does not aggravate the ET-1-induced acute myocardial ischemia and the release of purine metabolites, suggesting that endogenous nitrogen monoxide is not a supplementary factor to purine metabolites in this type of coronary adaptive responses.

AN 2005:138870 BIOSIS
 DN PREV200500137241

TI Nitrogen oxide blockade does not aggravate the endothelin-1-induced myocardial ischemia and release of purine metabolites from the dog heart.

AU Zima, Endre [Reprint Author]; Kekesi, Violetta; Nagy, Andrea; Barat, Erzsehet; Huszar, Eva; Toma, Ildiko; Merkely, Bela; Juhasz-Nagy, Alexander

CS Dept Cardiovasc Surg, Semmelweis Univ Med, Varosmajor U 68, H-1122, Budapest, Hungary
 endzim@primposta.hu

SO Journal of Cardiovascular Pharmacology, (November 2004) Vol. 44, No. Suppl. 1, pp. S313-S317. print.
 CODEN: JPCPDT. ISSN: 0160-2446.

DT Article
 LA English
 ED Entered STN: 6 Apr 2005
 Last Updated on STN: 6 Apr 2005

=> s L14 and complex/ab

L16 16 L14 AND COMPLEX/AB

=> dup rem L16

PROCESSING COMPLETED FOR L16

L17 5 DUP REM L16 (11 DUPLICATES REMOVED)

=> d L17 1-5 ti

L17 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1

TI Intrasteric control of AMPK via the gamma1 subunit AMP allosteric
regulatory site.

L17 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 2

TI Serine 948 and Threonine 1042 are crucial residues for allosteric
regulation of Escherichia coli carbamoylphosphate synthetase and
illustrate coupling effects of activation and inhibition pathways.

L17 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 3

TI Crystal structure of Tritrichomonas foetus inosine-5'-monophosphate
dehydrogenase and the enzyme-product complex.

L17 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 4

TI Tritrichomonas foetus: A strategy for structure-based inhibitor design of
a protozoan inosine-5'-monophosphate dehydrogenase.

L17 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 5

TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES
AND THEIR COMPONENTS.

=> d l17 5 ti abs bib

L17 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 5

TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES
AND THEIR COMPONENTS.

AB PMR was used to investigate the specificity of interaction of
arginine and lysine with [calf thymus] DNA and the polynucleotides
poly (G), poly (I), poly (A), poly (C), poly (U) and an interaction of
histones F1 and F2a1 with poly (I). In all cases complexes of
arginine are more stable and more specific than those of lysine.
The interaction of arginine with polynucleotides decreases in
the following order: G > I > C ≥ A > U. Changes in the solubility
of the purine nucleosides adenosine, guanosine and inosine and
the pyrimidine bases thymine and cytosine in the presence of glycine,
arginine and lysine were studied. The apparent association
constants for the complex formation were calculated. In
addition to specific H-bonds between the arginine guanidine
group and the O-6, N-7 of guanine and inosine or the O-2, N-3 of
cytosine, the formation of specific H-bonds probably takes place between
the carboxyl group of the amino acid and the H-N1, H-N2 guanine groups.

AN 1976:170387 BIOSIS

DN PREV197662000387; BA62:387

TI SPECIFICITY OF INTERACTION OF ARGININE AND LYSINE WITH POLY NUCLEOTIDES
AND THEIR COMPONENTS.

AU BRUSKOV V I; BUSHUEV V N

SO Bioorganicheskaya Khimiya, (1975) Vol. 1, No. 11, pp. 1606-1615.
CODEN: BIKHD7. ISSN: 0132-3423.

DT Article

FS BA

LA Unavailable

=> s L14 and salt/ab

L18 12 L14 AND SALT/AB

=> dup rem L18

PROCESSING COMPLETED FOR L18

L19 10 DUP REM L18 (2 DUPLICATES REMOVED)

=> d L19 1-10 ti

L19 ANSWER 1 OF 10 USPATFULL on STN

TI Inosine L-Arginine salt and uses thereof

L19 ANSWER 2 OF 10 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF

TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION

L19 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter

L19 ANSWER 4 OF 10 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1

TI Mast cell amines and inosine-induced vasoconstriction in the rat hind limb.

L19 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Changes in nutritional components of Toha-jeot (salt-fermented Toha shrimp) during fermentation

L19 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI The taste compounds of fermented squid, Loligo kubiensis

L19 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Stabilizing α -lipoic acid in pharmaceutical solutions

L19 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Employment of microinjection techniques and large nerve and muscle fibers in the study of active transport and muscular contraction

L19 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI The effects of injecting energy-rich phosphate compounds on the active transport of ions in the giant axons of Loligo

L19 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

TI Amino acids and growth factors in chemically defined medium for Drosophila

=> d l19 1 2 3 4 7 ti abs bib

L19 ANSWER 1 OF 10 USPATFULL on STN

TI Inosine L-Arginine salt and uses thereof

AB The present invention discloses an inosine. L-arginine salt, compositions containing the salt, and methods of using the salt and said compositions for cell activation and/or plant growth promotion. The salt can be stored and transported as a solid and dissolves quickly and efficiently when needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:247954 USPATFULL

TI Inosine L-Arginine salt and uses thereof

IN Kurauchi, Masahiko, Kanagawa, JAPAN

Miyazawa, Yuki, Kanagawa, JAPAN

Sato, Hiroyuki, Kanagawa, JAPAN

PI US 2004192553 A1 20040930

AI US 2004-808536 A1 20040325 (10)

RLI Continuation of Ser. No. WO 2002-JP9184, filed on 10 Sep 2002, UNKNOWN
 PRAI JP 2001-297011 20010927
 DT Utility
 FS APPLICATION
 LREP AJINOMOTO CORPORATE SERVICES, LLC, INTELLECTUAL PROPERTY DEPARTMENT,
 1120 CONNECTICUT AVE., N.W., WASHINGTON, DC, 20036
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN 4 Drawing Page(s)
 LN.CNT 368
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 10 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
 TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
 ABEN A novel substance inosine/L-arginine salt
 and a cell activator or a plant growth
 promoter prepared by dissolving the salt in water. These
 agents are inosine preparations
 which can be distributed as a solid product and quickly dissolved before
 using.
 ABFR La presente invention concerne une nouvelle substance, un sel d'
 inosine/de
 L-arginine et un activateur cellulaire ou promoteur de
 croissance vegetale
 prepare par dissolution du sel dans l'eau. Les agents sont des
 preparations d'inosine qui peuvent etre distribuees
 sous la forme d'un produit solide et dissoutes rapidement avant
 utilisation.
 AN 2003029265 PCTFULL ED 20030416 EW 200315
 TIEN INOSINIE/L-ARGININE SALT AND USE THEREOF
 TIFR SEL D'INOSINE/DE L-ARGININE ET SON UTILISATION
 IN KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
 MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP];
 SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP]
 PA AJINOMOTO CO., INC., 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JP
 [JP, JP], for all designates States except US;
 KURAUCHI, Masahiko, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
 MIYAZAWA, Yuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only;
 SATO, Hiroyuki, Ajinomoto Co., Inc., 1-1, Suzuki-cho, Kawasaki-ku,
 Kawasaki-shi, Kanagawa 210-8681, JP [JP, JP], for US only
 AG SHIMOKOSHI, Masao, 9th Fl., Taka-ai Bldg., 15-2, Nihombashi 3-chome,
 Chuo-ku, Tokyo 103-0027, JP
 LAF Japanese
 LA Japanese
 DT Patent
 PI WO 2003029265 A1 20030410
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW
 MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN
 TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL
 PT SE SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-JP9184 A 20020910
 PRAI JP 2001-2001-297011 20010927

L19 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
 AB The L-arginine salt of inosine (I) enhances the solubility of inosine and enables easy translocation of the inosine. The L-arginine and inosine form salt at 1:1 ratio. I is useful for stimulation of cell activity and promotion of plant growth such as rooting. Preparation of I and promotion of growth of bent grass with I were shown.
 AN 2003:257896 CAPLUS
 DN 138:250168
 TI Inosine arginine salt for cell activity-stimulating agent and plant growth promoter
 IN Kurauchi, Masahiko; Miyazawa, Yoshinori; Sato, Hiroyuki
 PA Ajinomoto Co., Inc., Japan
 SO Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003096090	A2	20030403	JP 2001-297011	20010927
	WO 2003029265	A1	20030410	WO 2002-JP9184	20020910
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1547585	A	20041117	CN 2002-816591	20020910
	US 2004192553	A1	20040930	US 2004-808536	20040325
PRAI	JP 2001-297011	A	20010927		
	WO 2002-JP9184	A1	20020910		

L19 ANSWER 4 OF 10 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 DUPLICATE 1
 TI Mast cell amines and inosine-induced vasoconstriction in the rat hind limb.
 AB Under certain circumstances injected inosine causes a net vasoconstrictive effect on the arterioles, which has been attributed to 5-hydroxytryptamine (5HT) released in response to adenosine type 3 (A-3) receptor stimulation of mast cells residing in the adventitia. We have sought further evidence for this hypothesis using blood vessels of the rat hind limb perfused in vitro at constant rate with a gelatin-containing physiological salt solution. Injection of inosine (2.7mg) caused a rise in perfusion pressure, which was only slightly increased by inclusion of N-nitro-L-arginine methyl ester (100 mu-M) in the perfusate. Inclusion in the perfusate of cyproheptadine (1 mu-M), compound 48/80 (1 mu-g/ml), 8-phenyltheophylline (1 mu-M) or 8-cyclopentyl-1,3 dipropylxanthine (0.1 mu-M) greatly reduced the pressor response to inosine. The pressor effect of injected 5HT (400 mu-g) was abolished by pre-treatment with cyproheptadine, but not by pre-treatment with compound 48/80. These results suggest that the net pressor response to injected inosine was mainly the result of an A1 receptor-mediated release of 5HT, most probably from mast cells. No evidence was found for an involvement of A-3 receptor stimulation.
 AN 1997:321098 BIOSIS
 DN PREV199799611586
 TI Mast cell amines and inosine-induced vasoconstriction in the rat hind limb.

AU Northover, A. M. [Reprint author]; Northover, B. J.
 CS Dep. Pharmaceutical Sci., Sch. Applied Sci., De Montfort Univ., Leicester
 LE1 9BH, UK
 SO Mediators of Inflammation, (1997) Vol. 6, No. 2, pp. 141-145.
 ISSN: 0962-9351.
 DT Article
 LA English
 ED Entered STN: 26 Jul 1997
 Last Updated on STN: 26 Jul 1997

L19 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Stabilizing α -lipoic acid in pharmaceutical solutions
 AB The light stability of α -lipoic acid in pharmaceutical solns. was
 increased by the addition of 70 mg/l. vitamin B6 or a molar equivalent amount
 of a

vitamin B6 salt or H3PO4 ester. For example, a stabilized solution
 contained KH2PO4 1.36, Na2SO4.10H2O 0.64, NaOAc.3H2O 1.36, Na2CO3 1.64,
 L-malic acid 2.5, sorbitol 50.0, xylitol 50.0, choline chloride 4.0,
 methionine 2.0, arginine 3.5, glycine 1.0, orotic acid 0.2,
 inosine 0.05, adenine 0.01, α -lipoic acid 0.20, nicotinic
 acid amide 0.20, pyridioxine-HCl 0.20, and inositol 0.20 g/l. in 0.5 ml
 EtOH and 500 ml H2O.

AN 1972:17803 CAPLUS
 DN 76:17803
 TI Stabilizing α -lipoic acid in pharmaceutical solutions
 IN Roessler, Richard; Mader, Helmut
 PA Pfrimmer, J., und Co.
 SO Ger., 4 pp.
 CODEN: GWXXAW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 1617740	A	19711104	DE 1967-P43060	19670925
PRAI	DE 1967-P43060	A	19670925		

=> d his

(FILE 'HOME' ENTERED AT 13:21:40 ON 12 JUL 2006)

FILE 'REGISTRY' ENTERED AT 13:21:53 ON 12 JUL 2006

L1 1 S INOSINE/CN
 L2 2 S ARGININE/CN
 EXP INOSINE
 EXP INOSINE/CN
 SEL L1
 SEL L2

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
 DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:23:09 ON 12 JUL 2006
 SEA (E1-E27) AND (E28-E44)

 2 FILE ADISCTI
 5 FILE AGRICOLA
 5 FILE ANABSTR
 29 FILE AQUASCI
 3 FILE BIOENG
 88 FILE BIOSIS
 17 FILE BIOTECHABS
 17 FILE BIOTECHDS
 24 FILE BIOTECHNO

20 FILE CABA
 396 FILE CAPLUS
 2 FILE CEABA-VTB
 2 FILE CROPU
 2 FILE DDFB
 9 FILE DDFU
 39 FILE DGENE
 8 FILE DISSABS
 2 FILE DRUGB
 5 FILE DRUGMONOG2
 10 FILE DRUGU
 84 FILE EMBASE
 34 FILE ESBIODBASE
 1 FILE FROSTI
 30 FILE FSTA
 308 FILE GENBANK
 63 FILE IFIPAT
 11 FILE JICST-EPLUS
 26 FILE LIFESCI
 82 FILE MEDLINE
 11 FILE OCEAN
 23 FILE PASCAL
 1 FILE PHIN
 4 FILE PROMT
 1 FILE RDISCLOSURE
 71 FILE SCISEARCH
 81 FILE TOXCENTER
 7417 FILE USPATFULL
 659 FILE USPAT2
 54 FILE WPIDS
 54 FILE WPINDEX
 2 FILE DPCI
 527 FILE EPFULL
 93 FILE FRFULL
 53 FILE GBFULL
 7 FILE INPADOC
 2 FILE JAPIO
 3 FILE PATDPAFULL
 6553 FILE PCTFULL
 1 FILE PIRA

L3 QUE ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOSIDE"/BI O

FILE 'BIOSIS, EMBASE, MEDLINE, USPATFULL, PCTFULL, EPFULL, CAPLUS'
 ENTERED AT 13:36:40 ON 12 JUL 2006

L4 15147 S (E1-E27) AND (E28-E44)

FILE 'REGISTRY' ENTERED AT 13:38:34 ON 12 JUL 2006
 EXP ARGININE/CN
 EXP ARGININE INOSINATE/CN

FILE 'BIOSIS, EMBASE, MEDLINE, USPATFULL, PCTFULL, EPFULL, CAPLUS'
 ENTERED AT 13:39:17 ON 12 JUL 2006

L5 9456 S L4 AND SOLUBILITY
 L6 5 S L5 AND AGRININE
 L7 0 S L5 AND (ARGININE(W) INOSINATE)
 L8 0 S L5 AND (INOSINE(W) ARGINATE)
 L9 8073 S L5 AND SALT
 L10 1830 S L5 NOT PY>2000
 L11 57015 S ARGININE/TI
 L12 12 S ARGININE/TI AND INOSINE/TI
 L13 5 DUP REM L12 (7 DUPLICATES REMOVED)
 L14 223 S ARGININE/AB AND INOSINE/AB
 L15 2 S L14 AND SOLUBILITY/AB
 L16 16 S L14 AND COMPLEX/AB

L17 5 DUP REM L16 (11 DUPLICATES REMOVED)
L18 12 S L14 AND SALT/AB
L19 10 DUP REM L18 (2 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	75.64	329.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

STN INTERNATIONAL LOGOFF AT 13:47:28 ON 12 JUL 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> exp inosine/cn

E1	1	INOSINATE NUCLEOSIDASE/CN
E2	1	INOSINATE PYROPHOSPHORYLASE/CN
E3	1 -->	INOSINE/CN
E4	1	INOSINE (5'-), 5'-(PENTAHYDROGEN TETRAPHOSPHATE)/CN
E5	1	INOSINE 2',3',5'-TRINITRATE/CN
E6	1	INOSINE 2',5'-DIPHOSPHATE/CN
E7	1	INOSINE 2'-MONOPHOSPHATE/CN
E8	1	INOSINE 3',5'-CYCLIC MONOPHOSPHATE/CN
E9	1	INOSINE 3',5'-DIPHOSPHATE/CN
E10	1	INOSINE 3',5'-DIPHOSPHATE, 5'-ANHYDRIDE WITH H2SO4/CN
E11	1	INOSINE 3',5'-MONOPHOSPHATE/CN
E12	1	INOSINE 3'-(HEXAHYDROGEN PENTAPHOSPHATE), 3'.FWDARW.5'-ESTER WITH 2',3'-O-(1-ETHOXY-2-(((PHENYLMETHOXY) CARBONYL) AMINO) PR OPYLIDENE) INOSINE/CN

=> exp arginine/cn

E1	1	ARGININANILIDE, NA,NQ,NQ-TRIS (PHENYLCARBAM OYL)-, L-/CN
E2	1	ARGININANILIDE, N2-BENZOYL-/CN
E3	2 -->	ARGININE/CN
E4	1	ARGININE B-NAPHTHYLAMIDE/CN
E5	1	ARGININE 2,2,2-TRICHLOROETHYL ESTER/CN
E6	1	ARGININE 2,3-AMINOMUTASE/CN
E7	1	ARGININE 2,3-AMINOMUTASE (STREPTOMYCES GRISEOCHROMOGENES GEN E BLSG)/CN
E8	1	ARGININE 2-MONOOXYGENASE/CN
E9	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN
E10	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E SCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN
E11	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E SCHERICHIA COLI STRAIN O157:H7 GENE ECS0943)/CN
E12	1	ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (E SCHERICHIA COLI STRAIN O157:H7 GENE ECS0946)/CN

=> exp isoprinosine

E1	1	ISOPRINOSIN/BI
E2	1	ISOPRINOSINA/BI
E3	1 -->	ISOPRINOSINE/BI
E4	1	ISOPRINTZIANIC/BI
E5	5	ISOPRISTIMERIN/BI
E6	33	ISOPRO/BI
E7	1	ISOPROBENPHOS/BI

```

E8          1      ISOPROBO/BI
E9          1      ISOPROBOTRI/BI
E10         1      ISOPROBOTRIAN/BI
E11         5      ISOPROBOTRYAN/BI
E12        16      ISOPROCARB/BI

```

```

=> s inosine/cn
L1          1 INOSINE/CN

```

```

=> sel L1
E1 THROUGH E27 ASSIGNED

```

```

=> file medline biosis embase scisearch uspatfull pctfull
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                ENTRY      SESSION
FULL ESTIMATED COST                               6.41          6.62

```

FILE 'MEDLINE' ENTERED AT 16:38:30 ON 12 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:38:30 ON 12 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:38:30 ON 12 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 16:38:30 ON 12 JUL 2006
COPYRIGHT (C) 2006 Univentio

```

=> s solubility(6a) (E1-E27)
L2          19 SOLUBILITY(6A) ((ATOREL/BI OR HXR/BI OR "HYPOXANTHINE RIBONUCLEOS
        IDE"/BI OR "HYPOXANTHINE RIBOSIDE"/BI OR "HYPOXANTHINE 9-B-
        D-RIBOFURANOSIDE"/BI OR "HYPOXANTHINE, 9-B-D-RIBOFURANOSYL-"
        /BI OR HYPOXANTHOSINE/BI OR INO/BI OR INOSIE/BI OR INOSINE/BI OR
        "NSC 20262"/BI OR OXIAMIN/BI OR PANHOLIC-L/BI OR RIBONOSINE/BI
        OR SELFER/BI OR TROPHICARDYL/BI OR "1,9-DIHYDRO-9-B-D-RIBOFU
        RANOSYL-6H-PURIN-6-ONE"/BI OR 12712-98-0/BI OR 132953-54-9/BI OR
        28861-88-3/BI OR 292853-81-7/BI OR 4181-51-5/BI OR 58-63-9/BI OR
        "6H-PURIN-6-ONE, 1,9-DIHYDRO-9-B-D-RIBOFURANOSYL-"/BI OR
        691344-25-9/BI OR 740029-83-8/BI OR 9-B-D-RIBOFURANOSYLHYPOX
        ANTHINE/BI))

```

```

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3          16 DUP REM L2 (3 DUPLICATES REMOVED)

```

```

=> d L3 1-16 ti

```

```

L3  ANSWER 1 OF 16  USPATFULL on STN
TI   Inosine L-Arginine salt and uses thereof

```

```

L3  ANSWER 2 OF 16  USPATFULL on STN
TI   Buoyant polymer particles for delivery of therapeutic agents to the
      central nervous system

```

```

L3  ANSWER 3 OF 16      PCTFULL  COPYRIGHT 2006 Univentio on STN
TIEN BUOYANT POLYMER PARTICLES FOR DELIVERY OF THERAPEUTIC AGENTS TO THE
      CENTRAL NERVOUS SYSTEM
TIFR ARTICLES POLYMERES FLOTTANTS POUR L'ADMINISTRATION D'AGENTS
      THERAPEUTIQUES AU SYSTEME NERVEUX CENTRAL

```


L3 ANSWER 4 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN WATER-SWELLABLE POLYMERS
 TIFR POLYMERES GONFLABLES DANS L'EAU

L3 ANSWER 5 OF 16 USPATFULL on STN
 TI Compositions and methods for the therapy and diagnosis of colon cancer

L3 ANSWER 6 OF 16 USPATFULL on STN
 TI Compositions and methods for the therapy and diagnosis of pancreatic cancer

L3 ANSWER 7 OF 16 USPATFULL on STN
 TI Compositions and methods for the therapy and diagnosis of colon cancer

L3 ANSWER 8 OF 16 USPATFULL on STN
 TI Compositions and methods for the therapy and diagnosis of ovarian cancer

L3 ANSWER 9 OF 16 USPATFULL on STN
 TI Plant-root growth promoting agent

L3 ANSWER 10 OF 16 USPATFULL on STN
 TI Plant-root growth promoting agent

L3 ANSWER 11 OF 16 MEDLINE on STN DUPLICATE 1
 TI Synthesis of RNA containing inosine: analysis of the sequence requirements for the 5' splice site of the Tetrahymena group I intron.

L3 ANSWER 12 OF 16 USPATFULL on STN
 TI Purification of inosine from guanosine

L3 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
 TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET D'UTILISATION

L3 ANSWER 14 OF 16 USPATFULL on STN
 TI Ultrafiltration of fermentation broth containing nucleosides to separate inosine and guanosine from the broth

L3 ANSWER 15 OF 16 USPATFULL on STN
 TI INOSINE DERIVATIVES

L3 ANSWER 16 OF 16 USPATFULL on STN
 TI INOSINE DERIVATIVES

=> d L3 5 6 7 8 9 10 12 13 15 16 ti abs bib

L3 ANSWER 5 OF 16 USPATFULL on STN
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:237907 USPATFULL
 TI Compositions and methods for the therapy and diagnosis of colon cancer
 IN King, Gordon E., Shoreline, WA, UNITED STATES
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,
PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul
2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 16 USPATFULL on STN
TI Compositions and methods for the therapy and diagnosis of pancreatic
cancer
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly pancreatic cancer, are disclosed. Illustrative compositions
comprise one or more pancreatic tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic
cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 16 USPATFULL on STN

TI Compositions and methods for the therapy and diagnosis of colon cancer
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:272801 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Stolk, John A., Bothell, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Chenault, Ruth A., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002150922 A1 20021017

AI US 2001-998598 A1 20011116 (9)

PRAI US 2001-304037P 20010710 (60)

US 2001-279670P 20010328 (60)

US 2001-267011P 20010206 (60)

US 2000-252222P 20001120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 16 USPATFULL on STN

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:243051 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES

Jones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002132237 A1 20020919

AI US 2001-867701 A1 20010529 (9)

PRAI US 2000-207484P 20000526 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent
AB Herein are disclosed, a plant-root growth promoting agent, which comprises inosine as the effective ingredient, as well as a method for promoting plant root growth, which comprise applying such plant-root growth promoting agent to the soil or, in the case of hydroponics, to the hydroponic water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:158224 USPATFULL
TI Plant-root growth promoting agent
IN Murayama, Akira, Morotomi-machi, Japan
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
PI US 6291398 B1 20010918
AI US 1999-469298 19991222 (9)
RLI Continuation of Ser. No. US 1997-962688, filed on 3 Nov 1997, now patented, Pat. No. US 6143695
PRAI JP 1996-298550 19961111
JP 1997-16006 19970314
DT Utility
FS GRANTED
EXNAM Primary Examiner: Clardy, S. Mark
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Plant-root growth promoting agent
AB Herein are disclosed, a plant-root growth promoting agent, which comprises inosine as the effective ingredient, as well as a method for promoting plant root growth, which comprise applying such plant-root growth promoting agent to the soil or, in the case of hydroponics, to the hydroponic water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:150115 USPATFULL
TI Plant-root growth promoting agent
IN Murayama, Akira, Morotomi-machi, Japan
PA Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)
PI US 6143695 20001107
AI US 1997-962688 19971103 (8)
PRAI JP 1996-298550 19961111
JP 1997-61006 19970314
DT Utility
FS Granted
EXNAM Primary Examiner: Clardy, S. Mark
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 595

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Purification of inosine from guanosine
AB An industrially advantageous process for producing an inosine-guanosine mixture having a higher weight ratio of guanosine/inosine than a starting mixture of nucleoside crystals and inosine substantially free of guanosine from which comprises adjusting an aqueous fluid containing 10 to 30% by weight/volume of a nucleoside mixture to a pH of 9.1 to 9.5,

wherein the total amount of inosine and guanosine is more than 95% by weight based on dry matters and the weight ratio of guanosine/inosine is 0.5 to 1, separating the resultant solids and then crystallizing inosine from the resulting solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 90:73582 USPATFULL
TI Purification of inosine from guanosine
IN Fujinawa, Shohei, Himeji, Japan
Sakamoto, Yoshinori, Takasago, Japan
Iizuka, Harumasa, Kakogawa, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4958017 19900918
AI US 1988-283805 19881213 (7)
PRAI JP 1987-320743 19871217
DT Utility
FS Granted
EXNAM Primary Examiner: Rollins, John W.; Assistant Examiner: Kunz, Gary L.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 423

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET
D'UTILISATION
ABEN Novel solute and crystal polymorphs of inosine. Also, a method of preparing a crystal polymorph of inosine comprising: providing a solvent; adding to the solvent at least about three grams of inosine per about 100 milliliters of the solvent; heating the solvent and the inosine at a predetermined rate to a temperature sufficient to cause the inosine to go into solution and to overcome the energy barriers which prevent the conversion of the inosine to another polymorphic configuration; cooling the solution at a predetermined rate for a predetermined period of time; and precipitating the crystal polymorph of inosine. The cooling step may comprise a single step or several steps. Freezing and lyophilization may be substituted for the precipitation step to produce the crystal polymorph. The invention further comprises a method of preparing solute polymorphs of inosine comprising dissolving inosine crystal polymorphs in a solvent. The solute polymorphs of the invention may also be prepared using the method described above for the preparation of crystal polymorphs, except that the step of precipitating and the steps of freezing and lyophilizing are not performed. Finally, according to the invention, there are provided anti-inflammatory compositions comprising an amount of a solute or crystal polymorph of inosine effective to reduce an inflammatory response in an animal and methods of reducing an inflammatory response in an animal comprising administering these compositions to the animal.
ABFR Nouvelles formes polymorphes de l'inosine, solutes et cristaux. Procédé de préparation d'un cristal polymorphe de l'inosine consistant a: utiliser un solvant; a ajouter au solvant au moins 3 grammes d'inosine pour 100 ml de solvant environ; a chauffer le solvant

et l'inosine, selon une vitesse predeterminee, pour atteindre une temperature suffisante pour provoquer la mise en solution de l'inosine et pour vaincre les barrieres energetiques qui empechent la conversion de l'inosine en une autre configuration polymorphe; a refroidir la solution selon une vitesse predeterminee pendant une periode predeterminee, et a precipiter le cristal d'inosine polymorphe. Le refroidissement peut s'effectuer en une ou plusieurs etapes. On peut remplacer la precipitation par la lyophilisation pour produire le cristal polymorphe. L'invention se rapporte egalement a une procede de preparation de solutes polymorphes de l'inosine consistant a dissoudre les cristaux polymorphes d'inosine dans un solvant. On peut egalement preparer des solutes polymorphes selon l'invention en utilisant le procede decrit precedemment pour la preparation de cristaux polymorphes, seules les etapes de precipitation et de lyophilisation etant omises. Compositions anti-inflammatoires comprenant une quantite d'un solute ou d'un cristal polymorphe d'inosine efficace pour attenuer la reponse inflammatoire d'un animal, et procedes de reduction de la reponse inflammatoire d'un animal consistant a administrer ces compositions a l'animal.

AN 1988009335 PCTFULL ED 20020507
 TIEN POLYMORPHS OF INOSINE AND METHODS OF MAKING AND USING THEM
 TIFR FORMES POLYMORPHES DE L'INOSINE, PROCEDES DE PREPARATION ET D'UTILISATION
 IN GORDON, Paul
 PA GORDON, Paul
 LA English
 DT Patent
 PI WO 8809335 A1 19881201
 DS W: AT AU BB BE BG BJ BR CF CG CH CM DE DK FI FR GA GB HU IT JP KP KR LK LU MC MG ML MR MW NL NO RO SD SE SN SU TD TG
 AI WO 1988-US1468 A 19880510
 PRAI US 1987-54,353 19870526

L3 ANSWER 15 OF 16 USPATFULL on STN
 TI INOSINE DERIVATIVES
 AB Complexes are formed in inosine and aminoalcohols of the formula ##SPC1##

Where R.sub.1 and R.sub.2 are lower alkyl and n is an integer of 2 to 4. The complexes have pharmacological activity including the ability to restore deteriorated learning and memory behavior. The preferred aminoalcohol is dimethylamino isopropanol. The preferred ratio of inosine to aminoalcohol is 1:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 74:62050 USPATFULL
 TI INOSINE DERIVATIVES
 IN Gordon, Paul, Chicago, IL, United States
 PA Newport Pharmaceuticals, Inc., Newport Beach, CA, United States (U.S. corporation)
 PI US 3857940 19741231
 AI US 1972-311732 19721207 (5)
 RLI Division of Ser. No. US 1971-145929, filed on 21 May 1971, now Defensive Publication No. which is a division of Ser. No. US 1969-853864, filed on 28 Aug 1969, now patented, Pat. No. US 3646007, issued on 29 Feb 1972
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Roberts, Elbert L.

LREP Cushman, Darby & Cushman
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 16 USPATFULL on STN
TI INOSINE DERIVATIVES
AB Complexes are formed in inosine and amino-alcohols of the formula
##SPC1##

Where R.sub.1 and R.sub.2 are lower alkyl and n is an integer of 2 to 4.
The complexes having pharmacological activity including the ability to
restore deteriorated learning and memory behavior. The preferred
aminoalcohol is dimethylamino isopropanol. The preferred ratio of
inosine to aminoalcohol is 1:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 73:16662 USPATFULL
TI INOSINE DERIVATIVES
IN Gordon, Paul, Chicago, IL, United States
PA Newport Pharmaceuticals, Inc., Newport, CA, United States (U.S.
corporation)
PI US 3728450 19730417
AI US 1971-145929 19710521 (5)
RLI Division of Ser. No. US 1969-853864, filed on 28 Aug 1969, now patented,
Pat. No. US 3645007, issued on 29 Feb 1972
DT Utility
FS Granted
EXNAM Primary Examiner: Rose, Shep K.
LREP Cushman, Darby & Cushman
CLMN Number of Claims: 9
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s inosine-arginine
L4 0 INOSINE-ARGININE

=> s inosine(6a)arginine
L5 70 INOSINE(6A) ARGININE

=> s inosine(4a)arginine
L6 48 INOSINE(4A) ARGININE

=> s L6 not py>2001
L7 30 L6 NOT PY>2001

=> dup rem L7
PROCESSING COMPLETED FOR L7
L8 22 DUP REM L7 (8 DUPLICATES REMOVED)

=> d L8 1-22 ti

L8 ANSWER 1 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR LUTTE CONTRE LES BACTERIES SPORULEES

L8 ANSWER 2 OF 22 USPATFULL on STN
TI Method for producing of phthalocyanine compound

L8 ANSWER 3 OF 22 USPATFULL on STN
TI Cloning and expression of human GMP synthetase, its use in screening for

inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 4 OF 22 USPATFULL on STN

TI Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 5 OF 22 USPATFULL on STN

TI Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase

L8 ANSWER 6 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1

TI Feeding behavior in juvenile snook, *Centropomus undecimalis*. I. Individual effect of some chemical substances.

L8 ANSWER 7 OF 22 USPATFULL on STN

TI Method of making inosine monophosphate derivatives and immunopotentiating uses thereof

L8 ANSWER 8 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN IMMUNOPOTENTIATING INOSINE MONOPHOSPHATE 5'-NUCLEOTIDASE RESISTANT DERIVATIVES AND USES THEREOF

TIFR DERIVES DE L'INOSINE MONOPHOSPHATE AYANT DES PROPRIETES IMMUNOSTIMULATRICES ET RESISTANT A LA 5'-NUCLEOTIDASE, ET LEUR UTILISATION

L8 ANSWER 9 OF 22 USPATFULL on STN

TI Prophylactic and therapeutic composition for MRSA infection

L8 ANSWER 10 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN CLONING AND EXPRESSION OF HUMAN GMP SYNTHETASE, ITS USE IN SCREENING FOR INHIBITORS OF HUMAN GMP SYNTHETASE AND INHIBITORS OF HUMAN GMP SYNTHETASE

TIFR CLONAGE ET EXPRESSION DE LA SYNTHETASE HUMAINE GMP ET SON EMPLOI DANS LE DEPISTAGE DES INHIBITEURS DE LA SYNTHETASE DU GUANOSINE MONOPHOSPHATE (GMP) HUMAIN, ET INHIBITEURS DE LA SYNTHETASE DU GMP HUMAIN

L8 ANSWER 11 OF 22 MEDLINE on STN DUPLICATE 2

TI Immunostimulating properties of the complexes of inosine derivatives.

L8 ANSWER 12 OF 22 USPATFULL on STN

TI Method for producing L-tryptophan by fermentation

L8 ANSWER 13 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 3

TI ERGOGENIC NUTRITIONAL SUPPLEMENTATION IN EFFORTS OF SPORTING DOGS.

L8 ANSWER 14 OF 22 USPATFULL on STN

TI Transducible composite plasmid

L8 ANSWER 15 OF 22 USPATFULL on STN

TI Plasmid

L8 ANSWER 16 OF 22 USPATFULL on STN

TI *Moraxella bovis* protease vaccine

L8 ANSWER 17 OF 22 USPATFULL on STN

TI Composite plasmid

L8 ANSWER 18 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI CLINICAL EVALUATION OF PHARMACOLOGICAL THERAPY ON IDIOPATHIC MALE

INFERTILITY.

L8 ANSWER 19 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
TI POSTMORTEM METABOLISM OF SHORT-FINNED SQUID MUSCLE ILLEX-ILLECEBROSUS.

L8 ANSWER 20 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
TI TASTE COMPOUNDS OF FRESH WATER FISHES 5. SENSORY EVALUATION OF TASTE
COMPONENTS IN THE EXTRACT OF WILD COMMON CARP CYPRINUS-CARPIO AND KOREAN
SNAKEHEAD CHANNA-ARGUS MEAT.

L8 ANSWER 21 OF 22 MEDLINE on STN DUPLICATE 4
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide
interactions. Specificity of arginine . inosine
association.

L8 ANSWER 22 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
TI GENETICS AND SELECTION OF ENTOMO PATHOGENIC FUNGUS BEAUVERIA-BASSIANA PART
2 VIRULENCE OF AUXOTROPHIC MUTANTS OF BEAUVERIA-BASSIANA ON
DROSOPHILA-MELANOGASTER.

=> d L8 1 2 9 11 21 ti abs bib

L8 ANSWER 1 OF 22 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR LUTTE CONTRE LES BACTERIES SPORULEES
ABEN Methods for controlling spores in aqueous systems, especially closed
systems. These methods include contacting germinating agent with an
aqueous closed system for a sufficient period of time and under
non-hostile conditions so that spores capable of germinating can
germinate into vegetative cells, and subjecting the germinated
vegetative cells to biocidal treatment. These methods also include
contacting germinating agent with the aqueous system for a sufficient
period of time and under non-hostile conditions so that spores capable
of germinating can germinate into vegetative cells, subjecting the
germinated vegetative cells to biocidal treatment in a hostile
environment; and cycling between hostile and non-hostile environments.
ABFR L'invention concerne des procedes de lutte contre les spores dans les
systemes aqueux, notamment les systemes fermes. Lesdits procedes
consistent a mettre un agent de germination au contact d'un systeme
ferme aqueux dans des conditions non hostiles et suffisamment longtemps
pour que les spores susceptibles de germer puissent germer en cellules
vegetatives ; et a faire subir auxdites cellules vegetatives germees un
traitement biocide. Lesdits procedes consistent egalement a mettre un
agent de germination au contact du systeme aqueux dans des conditions
non hostiles et suffisamment longtemps pour que les spores susceptibles
de germer puissent germer en cellules vegetatives ; a faire subir
auxdites cellules vegetatives germees un traitement biocide dans un
environnement hostile ; et a les recycler entre des environnements
hostile et non hostile.

AN 2001066471 PCTFULL ED 20020822
TIEN CONTROL OF SPORE FORMING BACTERIA IN AQUEOUS SYSTEMS
TIFR LUTTE CONTRE LES BACTERIES SPORULEES
IN BREEN, Alexander, W.;
TAYLOR, Charles;
SMITH, Kelly, S.
PA HERCULES INCORPORATED
DT Patent
PI WO 2001066471 A2 20010913
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX

MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
 AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
 IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
 NE SN TD TG

AI WO 2001-US6132 A 20010223
 PRAI US 2000-09/521,422 20000308

L8 ANSWER 2 OF 22 USPATFULL on STN

TI Method for producing of phthalocyanine compound

AB A method for producing a novel phthalocyanine compound which excels in yield and purity, allows no introduction of a chlorine atom into the phthalocyanine skeleton, and possesses relatively bulky substituents is provided. This method is characterized by causing an orthophthalonitrile compound having a substituent exhibiting smaller $\sigma_{\text{sub.p}}$ values than $\sigma_{\text{sub.m}}$ values in the Hammett's rule to react with a metal oxide in the presence of a compound forming in the aqueous solution thereof at 25° C. an acid or conjugate acid having a dissociation index pKa (the logarithmic value of the reciprocal of the dissociation constant of the acid or conjugate acid) of not more than 7.0.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:28131 USPATFULL

TI Method for producing of phthalocyanine compound

IN Aoki, Minoru, Ibaraki, Japan

Kaieda, Osamu, Ibaraki, Japan

PA Nippon Shokubai Co., Ltd., Osaka-fu, Japan (non-U.S. corporation)

PI US 6034236 20000307

AI US 1998-92719 19980605 (9)

PRAI JP 1997-148101 19970605

JP 1998-7020 19980116

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada, Pavanaram K

LREP Fish & Richardson P.C.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 22 USPATFULL on STN

TI Prophylactic and therapeutic composition for MRSA infection

AB The invention provides an anti-MRSA prophylactic/therapeutic composition containing as an active ingredient at least one nucleic acid component selected from among inosine, guanosine n'-monophosphate (GMP) (n'=2', 3'or 5'), uridine and thymidine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 95:50167 USPATFULL

TI Prophylactic and therapeutic composition for MRSA infection

IN Yamamoto, Sigeru, Naha, Japan

Yokoyama, Hiroomi, Naruto, Japan

PA Otsuka Pharmaceutical Factory, Inc., Naruto, Japan (non-U.S. corporation)

PI US 5422343 19950606

AI US 1993-26744 19930305 (8)

PRAI JP 1992-340523 19921221

DT Utility

FS Granted

EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Varma, Anita

LREP Armstrong, Westerman, Hattori, McLeland and Naughton

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 22 MEDLINE on STN DUPLICATE 2
TI Immunostimulating properties of the complexes of inosine derivatives.
AB The effects of the complexes of inosine (Ino) analogues of isoprinosine on the immune response to sheep red blood cells (SRBC), in plaque-forming cells assay (PFC), in mice spleen, and on the Fc-dependent SRBC phagocytosis in mice peritoneal macrophages were investigated. Molar ratios of 1:3 of the complexes of inosine with N,N-dimethylaminopropanol-2-p-acetaminobenzoate (isoprinosine), and 8-thioinosine with N,N-dimethylaminopropanol-2-p-acetaminobenzoate (OSI-177), inosine with L-arginine butyrate (OSI-2655), and 8-thioinosine with L-arginine butyrate (OSI-3648) were administered. The administered doses were 0.5, 5 and 50 mg/kg body weight. The compound OSI-2655 exceeded isoprinosine in PFC stimulation and phagocytosis activation. The compound OSI-3648 exceeded isoprinosine only in PFC stimulation in the case of immunization with a suboptimal SRBC dose. OSI-3648 stimulated the immune response in PRC better than isoprinosine, OSI-177, or OSI-2655, and maintained the ability to stimulate capture, but lost the ability to stimulate destruction processes of captured SRBC. L-Arginine butyrate in the doses equivalent to its content in the complexes did not affect the number of PFC. L-Arginine butyrate was able to stimulate the processes of destruction but its stimulation degree was inferior to the compound OSI-2655.

AN 96380110 MEDLINE
DN PubMed ID: 8788123
TI Immunostimulating properties of the complexes of inosine derivatives.
AU Poluektova L; Maurinsh Y; Lidaks M; Gromova N
CS Medical Academy of Latvia, Riga.
SO International journal of immunopharmacology, (1995 Nov) Vol. 17, No. 11, pp. 941-7.
Journal code: 7904799. ISSN: 0192-0561.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199701
ED Entered STN: 28 Jan 1997
Last Updated on STN: 28 Jan 1997
Entered Medline: 16 Jan 1997

L8 ANSWER 21 OF 22 MEDLINE on STN DUPLICATE 4
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.
AN 78190631 MEDLINE
DN PubMed ID: 658044
TI Thermodynamic and kinetic parameters of oligonucleotide--oligopeptide interactions. Specificity of arginine . inosine association.
AU Porschke D
SO European journal of biochemistry / FEBS, (1978 May) Vol. 86, No. 1, pp. 291-9.
Journal code: 0107600. ISSN: 0014-2956.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197808
ED Entered STN: 14 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 14 Aug 1978

=> d his

(FILE 'HOME' ENTERED AT 16:36:06 ON 12 JUL 2006)

FILE 'REGISTRY' ENTERED AT 16:36:25 ON 12 JUL 2006

EXP INOSINE/CN
EXP ARGININE/CN
EXP ISOPRINOSINE

L1 1 S INOSINE/CN
 SEL L1

FILE 'MEDLINE, BIOSIS, EMBASE, SCISEARCH, USPATFULL, PCTFULL' ENTERED AT
16:38:30 ON 12 JUL 2006

L2 19 S SOLUBILITY(6A) (E1-E27)
L3 16 DUP REM L2 (3 DUPLICATES REMOVED)
L4 0 S INOSINE-ARGININE
L5 70 S INOSINE(6A) ARGININE
L6 48 S INOSINE(4A) ARGININE
L7 30 S L6 NOT PY>2001
L8 22 DUP REM L7 (8 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
44.19	50.81

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 16:46:50 ON 12 JUL 2006